# Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder

> **NCT00635219** · PHASE3 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 766 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** Vortioxetine (Lu AA21004)
- **DRUG:** Vortioxetine (Lu AA21004)
- **DRUG:** Vortioxetine (Lu AA21004)
- **DRUG:** Duloxetine

## Key facts

- **NCT ID:** NCT00635219
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 766 (ACTUAL)
- **Last updated:** 2014-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635219, "Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00635219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*